A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer.

James J HardingAndrew X ZhuTodd M BauerToni K ChoueiriAlexander E Drilon Martin H VossCharles S FuchsGhassan K Abou-AlfaSameera R WijayawardanaXuejing Aimee WangBrian A MoserArantxa UruñuelaVolker WacheckJohanna C Bendell

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Ramucirumab plus emibetuzumab was safe and exhibited cytostatic antitumor activity. MET expression may help to select patients benefitting most from this combination treatment in select tumor types.

Keyphrases

advanced cancer
end stage renal disease
palliative care
ejection fraction
chronic kidney disease
newly diagnosed
poor prognosis
peritoneal dialysis
prognostic factors
patient reported
replacement therapy